Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

Abstract

There is no clear evidence that ATIs have an impact on efficacy or safety, nor a need to measure or prevent them in clinical practice. Circulating drug concentration may be a more relevant measure of immunogenicity.

Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies

“…Robust immunoassays are critical for evaluation of antibody immunogenicity (IM) during both preclinical and clinical phases (40)(41)(42)(43)(44). Various methodologies have been used for IM testing; however, these methodologies differ with respect to sensitivity for measuring both low-and high-affinity antibody responses (45,46).…”

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

“…Due to the fact that the production of antibodies to infliximab is associated with the lack of efficacy or infusion reactions, it is recommended to add methotrexate to prevent the formation of antibodies. Several papers, mainly in rheumatology, mention the positive effect of methotrexate (in gastroenterology also of azathioprine) to reduce the production of antibodies [2,[10][11][12][13][14][15][16]. Nevertheless, the beneficial effect of MTX on the formation of ATI in psoriatic patients is described only rarely [2,13].…”

Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives

“…However, although 60 to 80 percent of patients showed a good initial response to anti-TNF therapy for CD and UC, only one third of patients remained in clinical remission without steroids at one year 45) . Currently, IFX (Remicade; Mitsubishi Tanabe Pharma Corp, Tokyo, Japan) is a chimeric immunoglobulin G (IgG) human (75%)/murine (25%) mAb administered by intravenous infusion, is indicated for induction and maintenance of remission in adult and paediatric CD and for induction and maintenance of remission in patients with UC 49) . IFX is also approved for other chronic inflammatory conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.…”